期刊文献+

PIK3CA及PDK1在乳腺浸润性导管癌中的表达及临床意义 被引量:1

Expression of PIK3CA and PDK1 in breast cancer and their clinical significance
下载PDF
导出
摘要 目的探讨PIK3CA、PDK1在乳腺浸润性导管癌中的表达情况及其临床病理学意义。方法采用免疫组织化学SP法及RT-PCR法检测160例浸润性导管癌及对应癌旁正常组织中PIK3CA和PDK1的表达情况,并分析二者在不同组织中表达的差异及其与乳腺癌临床病理学特征的相关性。结果免疫组化检测显示PIK3CA和PDK1在浸润性导管癌中的表达均高于癌旁组织,差异有统计学意义(P<0.001),且PIK3CA的表达与淋巴结转移、HER2阳性表达及Ki-67指数有一定相关性(P<0.01),PDK1的表达与淋巴结转移、ER阳性表达及Ki-67指数有一定相关性(P<0.01)。RT-PCR结果显示,乳腺癌组织中PIK3CA和PDK1 mRNA水平相对表达量显著高于正常组织中mRNA水平相对表达量(P<0.001),差异有统计学意义。结论 PIK3CA和PDK1在乳腺癌中高表达,表明二者参与了乳腺癌的发生、发展过程,且对乳腺癌分子分型及预后的评估及后续治疗提供一定参考价值。 Objective To investigate the expression of PIK3CA and PDK1 in breast invasive ductal carcinoma and their clinicopathological significance.Methods Immunohistochemical S-P and RT-PCR methods were used to detect the expression of PIK3CA and PDK1 in 160 cases of invasive ductal carcinoma and corresponding adjacent normal tissues,and then to analyze the difference of expression of PIK3CA and PDK1 in different tissues and their correlation with clinical pathological features in breast cancer.Results Immunohistochemical examination showed that the expression of PIK3CA and PDK1 in invasive ductal carcinoma was higher than that in the adjacent tissues,with statistically significant difference(P<0.001).Moreover,the expression of PIK3CA had certain correlation with lymph node metastasis,HER2 positive expression and Ki-67 index(P<0.01);the expression of PDK1 had certain correlation with lymph node metastasis,ER positive expression and Ki67 index of the tumor(P<0.01).RT-PCR results showed that the relative expression of PIK3CA and PDK1 mRNA levels in breast cancer tissues was significantly higher than that in normal tissues(P<0.001),and the difference was statistically significant.Conclusion The high expression of PIK3CA and PDK1 in breast cancer indicates that they are involved in the development of breast cancer,and provide certain reference value for the evaluation of molecular typing and prognosis of breast cancer and the subsequent treatment.
作者 刘铭 苗娜 李俊芝 张巍 王志强 LIU Ming;MIAO Na;LI Jun-zhi;ZHANG Wei;WANG Zhi-qiang(Department of Pathology,the First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,China;Department of Encephalopathy Center,the Third Pepole’s Hospital of Urumqi,Urumqi 830000,China)
出处 《诊断病理学杂志》 2020年第8期573-577,共5页 Chinese Journal of Diagnostic Pathology
基金 新疆维吾尔自治区自然科学基金青年基金项目(2017D01C316)。
关键词 浸润性导管癌 PIK3CA PDK1 免疫组化 PT-PCR Invasive ductal carcinoma PIK3CA PDK1 Immunohistochemical PT-PCR
  • 相关文献

参考文献4

二级参考文献40

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:165
  • 2Laurent-Puiq P,Aqostini J,Maley K. Colorectaloncogenesis[J].Bulletin Du Cancer,2010,(11):1311-1321.
  • 3Izycka-Swieszewska E,Brzeskwiniewicz M,Wozniak A. EGFR,PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours[J].Folia Neuro Pathol,2010,(04):238-245.
  • 4Dbouk H A,Backer J M. A beta version of life:p110β takes center stage[J].Oncotarget,2010,(08):729-733.
  • 5Carnero A,Blanco-Aparicio C,Renner O. The PTEN/PI3K/AKT signalling pathway in cancer,therapeutic implications[J].Current Cancer Drug Targets,2008,(03):187-198.doi:10.2174/156800908784293659.
  • 6Yuan T L,Cantley L C. PI3K pathway alterations in cancer:variations on a theme[J].Oncogene,2008,(41):5497-5510.doi:10.1038/onc.2008.245.
  • 7Xing M. Recent advances in molecular biology of thyroid cancer and their clinical implications[J].Otolaryngologic Clinics of North America,2008,(06):1135-1146.
  • 8Zhao L,Vogt P K. Helical domain and kinase domain mutations in p110 of Phosphate-dylinositol 3-kinase induce gain of function by differert mechanisms[J].Proceedings of the National Academy of Sciences(USA),2008,(07):2652-2657.
  • 9Hutti J E,Pfefferle A D,Russell S C. Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation[J].Cancer Research,2012,(13):3260-3269.
  • 10Janku F,Wheler J J,Westin S N. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations[J].Journal of Clinical Oncology,2012,(08):777-782.

共引文献20

同被引文献12

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部